MaxCyte, Inc. (LON:MXCT - Get Free Report) reached a new 52-week low during trading on Wednesday . The company traded as low as GBX 230 ($2.98) and last traded at GBX 240 ($3.11), with a volume of 86242 shares traded. The stock had previously closed at GBX 265 ($3.43).
MaxCyte Stock Performance
The stock's 50 day moving average is GBX 335.97 and its two-hundred day moving average is GBX 311.20. The stock has a market capitalization of £316.81 million, a price-to-earnings ratio of -8.79 and a beta of 1.13. The company has a current ratio of 9.81, a quick ratio of 14.38 and a debt-to-equity ratio of 8.59.
About MaxCyte
(
Get Free Report)
MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider MaxCyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MaxCyte wasn't on the list.
While MaxCyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
